ONXX
{"sector":"Healthcare","industry":"Drugs","symbol":"ONXX","company_name":"Onyx Pharmaceuticals, Inc.","exchange":"NASDAQ"}ONXX Articles
ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech...
Published:
Last Updated:
ThinkstockQuestcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Under Armour Inc. (NYSE: UA) may seem to have little to nothing in common on the surface. Questcor is in the pharmaceutical business, while...
Published:
Jon OggAny time you see a merger announcement, you see a myriad of press releases pertaining to law firms and lawyers investigating the terms of the deal. This is in one sense the new form of class...
Published:
ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc....
Published:
If you have analyzed the myriad earnings reports over the summer of 2013, the trend that you will notice is a lack of revenue growth from most major companies. Many have continued to grow earnings...
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Monday, July 29, 2013. They include FedEx, Hormel, Potash Corp., 3D Systems and Whole Foods.
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Monday, July 22, 2013. They include Crocs, General Electric, Juniper Networks and Nokia.
Published:
Last Updated:
When we screen stocks at the Wall Street firms we cover, we always are anxious to provide our readers with the stocks that the top firms feel have the most upside from current trading levels to their...
Published:
Last Updated:
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company...
Published:
Last Updated:
ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers...
Published:
Last Updated:
July 1, 2013: U.S. equity markets opened higher this morning after a blast of economic data from both Asia and Europe. In China, June manufacturing PMI slid lower. Japan’s economics minister said...
Published:
Last Updated:
ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ:...
Published:
Last Updated:
ThinkstockThe higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their portfolios. With the market currently teetering on what seems like an...
Published:
Last Updated:
ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the difference...
Published:
ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28%...
Published: